Title |
Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
|
---|---|
Published in |
Health and Quality of Life Outcomes, October 2006
|
DOI | 10.1186/1477-7525-4-80 |
Pubmed ID | |
Authors |
Kristina Secnik Boye, Louis S Matza, Alan Oglesby, Karen Malley, Sunny Kim, Risa P Hayes, Robert Brodows |
Abstract |
Patient-reported measures can be used to examine whether drug differences other than clinical efficacy have an impact on outcomes that may be important to patients. Although exenatide and insulin glargine appear to have similar efficacy for treatment of type 2 diabetes, there are several differences between the two treatments that could influence outcomes from the patient's perspective. The purpose of the current study was to examine whether the two drugs were comparable as assessed by patient-reported outcomes using data from a clinical trial in which these injectable medications were added to pre-existing oral treatment regimens. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 77 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 17 | 22% |
Researcher | 11 | 14% |
Student > Ph. D. Student | 10 | 13% |
Other | 9 | 11% |
Student > Bachelor | 6 | 8% |
Other | 12 | 15% |
Unknown | 14 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 34% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
Psychology | 6 | 8% |
Agricultural and Biological Sciences | 6 | 8% |
Nursing and Health Professions | 5 | 6% |
Other | 14 | 18% |
Unknown | 15 | 19% |